Gossamer Bio Secures Up to $250M Structured Private Placement to Fund Seralutinib Through FDA Approval

summarizeSummary

Gossamer Bio announced a structured private placement of up to $250 million, with $150 million committed, to fund seralutinib through potential FDA approval. The financing includes an initial $25 million closing, a $125 million second closing contingent on FDA acceptance of the NDA, and warrants for up to $100 million upon FDA approval.

check_boxKey Events · Financing and Capital Events · GOSS

• Up to $250M Private Placement

  Gossamer Bio entered into a securities purchase agreement for a private placement of up to $250 million, with $150 million committed from institutional investors including EcoR1 Capital, RA Capital Management, and Samsara BioCapital.

• Initial $25M Closing

  The initial closing on August 24, 2026 will issue pre-funded warrants for $25 million at $0.1399 per warrant, representing a common stock-equivalent price of $0.14, a discount to the current $0.2095 stock price.

• Second $125M Closing on FDA Acceptance

  An additional $125 million will fund upon FDA acceptance of the seralutinib NDA in PAH, expected in 2026. The purchase price will be the lesser of $0.1399 or the five-day VWAP preceding the second closing.

• FDA Approval Warrants for $100M

  At the second closing, investors will receive warrants exercisable upon FDA approval of seralutinib at $0.187 per share, potentially providing up to $100 million in additional proceeds.

auto_awesomeAnalysis · GOSS · Life Sciences

Gossamer Bio entered into a securities purchase agreement for a private placement of up to $250 million, with $150 million committed. The initial $25 million closes August 24, 2026, and an additional $125 million funds upon FDA acceptance of the seralutinib NDA. FDA Approval Warrants could add another $100 million if the drug is approved. The financing is highly dilutive at current prices — the initial pre-funded warrants are priced at $0.1399, a discount to the current $0.2095 stock price, and the second closing price may be even lower. However, the capital extends the company's cash runway into 2028, addressing the going concern warning disclosed in the recent 10-Q. The structure aligns funding with regulatory milestones, reducing near-term dilution risk if the NDA is not accepted.